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ABSTRACT Perﬂuorocarbons (PFCs) hold great promise for biomedical applications. However, relatively little is known about
the impact of these chemicals on membranes. We used unilamellar vesicles to explore the effects of PFCs onmembrane packing
and vesicle stability. Four clinically relevant PFCs with varying vapor pressures (PP1, 294 mbar; PP2, 141 mbar; PP4, 9.6 mbar;
and PP9, 2.9 mbar) were examined. Microscopy imaging and spectroscopic measurements suggest that PFCs, especially those
with high vapor pressures, lead to vesicle fusionwithin hours.Uponexposure toPP1andPP2 for 72 h, vesicles retaineda spherical
shape, but the size changed from;200 nm to;20–40mm. In addition,membrane packing underwentmarked changes during this
timeframe. A signiﬁcant decrease in water content in the lipid polar headgroup regions occurred during the ﬁrst 1–2-h exposure to
PFCs, followed by a steady increase in water content over time. Possible mechanisms were proposed to explain these dramatic
structural changes. The ﬁnding that chemically inert PFCs exhibited fusogenic activity andmarked changes in membrane surface
packing is novel, and should be considered when using PFCs for biomedical applications.
INTRODUCTION
Perﬂuorocarbons (PFCs) are a group of synthetic, chemically
inert, water-immiscible compounds. They are composed
mainly of C and F, and the C-F bond is highly stable (1).
Humans lack the enzymes required to cleave the C-F bond.
Within this context, PFCs are considered biologically inert.
Animal and clinical studies showed that PFCs are also
physiologically compatible.
Perﬂuorocarbons have many other unique properties that
lend great promise for biomedical applications. Perﬂuoro-
carbons dissipate heat and acoustical stress, and may prevent
carbonization of bone (2). They also have low surface tension.
This characteristic serves to stabilize the surfactant-deﬁcient
lung by reducing the amount of pressure required to inﬂate the
lung. In addition, because PFC liquids are incompressible,
they prevent the lung from completely collapsing during ex-
piration. These liquids also have high solubility of respiratory
gases, and work as an excellent transporter or exchanger for
oxygen and carbon dioxide. By ﬁlling the lungs with PFCs,
oxygen can be delivered to the lungs to treat severe respiratory
disease (2–4). Clinical studies of neonates and young children
showed that PFC-based liquid ventilation improves oxygen-
ation and lung function (5). Based on the same oxygen-
transporting phenomenon, PFC emulsionswere used as blood
substitutes (6–8). Perﬂuorocarbons may also be used to de-
liver pulmonary drugs (5,9), and to function as imaging
contrast agents (10–12). Preclinical studies also showed that
PFC vapor and neat liquids reduce inﬂammation and mitigate
damage in the lung (13,14).
Perﬂuorocarbon molecules are primarily uncharged, lipo-
philic entities. When they enter a cell, they must ﬁrst asso-
ciate with lipid bilayers in cell membranes (6). In vitro studies
demonstrated that cellular effects of PFCs correlate with their
lipid solubility (15). Thus, the most logical and fundamental
study to understand fully PFCs in cells or tissues would in-
volve a thorough investigation of interactions of PFCs with
lipid membranes. However, very few studies have been
performed to reveal the biophysical details and principles
underlying PFC-membrane interactions. The NMR work of
Ellena et al. (16) demonstrated that perﬂuorooctyl bromide
(PFOB) has limited lipid solubility in 1-palmitoyl-2-oleoyl-
L-a-phosphatidylcholine (POPC) bilayers, but inside the
bilayer, PFOB resides in the bilayer center (midplane region),
with its long axis aligned perpendicular to the membrane
normal. Perhaps because of this rather unusual disposition,
PFOB does not produce any signiﬁcant changes in either acyl
chain or headgroup structure (16). Gerber et al. (17) reported
that PFOB ﬂuidizes a dipalmitoyl-L-a-phosphatidylcholine
(DPPC) monolayer. Although these studies are interesting,
little is known about the effects of PFCs on membrane lateral
organization, bilayer packing, membrane morphology, and
the temporal evolution of those effects. Furthermore, PFOB
has a low vapor pressure (14.6 mbar) (17). The ﬁndings from
PFOB may not apply to PFCs with high vapor pressures (for
examples, see below).
Here, we used unilamellar vesicles, composed of either
POPC or cholesterol plus POPC, to explore the effects of
PFCs on membrane packing and vesicle stability. Four clin-
ically relevant PFCs, i.e., perﬂuoro-2-methylpentane (PP1,
294 mbar), perﬂuoromethylcyclohexane (PP2, 141 mbar),
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perﬂuoro-1,3,5-trimethylcyclohexane (PP4, 9.6 mbar), and
perﬂuoromethyldecalin (PP9, 2.9 mbar), were used (Fig. 1).
These PFCs exhibit a range of physicochemical properties
(e.g., vapor pressure), and were used in vivo for respiratory
applications. The oxygen gas solubility of these PFCs is
within a narrow range, and is thus unlikely to contribute a
marked confounding experimental inﬂuence. The vapor
pressures of PFCs are strongly correlated with the reduced
production of inﬂammatory mediators and increased lung
compliance (14,18). Our data from photon correlation spec-
troscopy, energy transfer-based lipid mixing assays, and
phase-contrast and electron microscopy suggest that PFCs,
especially those with high vapor pressures, lead to vesicle
aggregation/fusion on the timescale of hours. During this time
period, membrane packing, as revealed by the generalized
polarization (GP) of Laurdan (6-lauroyl-2-(dimethylamino)-
naphthalene) ﬂuorescence, also undergoes marked changes.




We obtained POPC and cholesterol from Avanti Polar Lipids (Alabaster, AL).
We obtained 6-lauroyl-2-(dimethylamino)naphthalene (Laurdan),N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine,
triethylammonium salt (NBD-PE), and lissamine rhodamine B 1,2-dihexa-
decanoyl-sn-glycero-3-phosphoethanolamine triethylammonium salt (rho-
damine-DHPE) from Invitrogen-Molecular Probes (Eugene, OR). We
purchased PP1, PP2, PP4, and PP9 from F2 Chemicals (Lancashire, UK).
The PFCs were stored at room temperature in a well-sealed vial.
Vesicle formation
Large unilamellar vesicles (LUVs), composed of either POPC or POPC plus
cholesterol (molar ratio, 7:3), were produced by the extrusion method (19).
Brieﬂy, POPC and cholesterol dissolved in chloroform were combined in the
appropriate proportions in a round-bottomed culture tube. Chloroform was
evaporated by a stream of nitrogen gas, and further dried under high vacuum
(;100–200millitorr), for more than 12 h. Then, we added 50mMTris buffer
containing 10 mM EDTA and 0.02% NaN3 (pH 7.2), prewarmed at 40C, to
the dry lipid ﬁlm. The tube was then ﬂushed with argon and capped, followed
by vortexing at ;40C, until all the lipids were dispersed into the aqueous
phase. After incubation at room temperature overnight, the lipid dispersions
were extruded (Lipex Biomembranes, Vancouver, British Columbia, Canada)
at 40C 10 times through two stacked 200-nm Nucleopore polycarbonate
ﬁlters (Whatman, Florham Park, NJ) under nitrogen gas pressure to form
LUVs. After extrusion, vesicles had a typical size of 175–190 nm in diam-
eter. The LUVswere then ﬂushed with argon and stored in a desiccator under
vacuum to prevent lipid oxidation (20) before use. For energy-transfer
experiments, vesicles were prepared in the same manner, except that the
molar ratio of membrane constituents was changed to 69:30:1 for POPC/
cholesterol/NBD-PE (or rhodamine-DHPE) mixtures.
Incubation of vesicles with PFCs
Vesicles were diluted to a lipid concentration of 300 mM and incubated with
PFC (5%, v/v) at room temperature. The ﬁnal volume of lipid vesicles plus
PFC was 5 mL. The mixture was placed in a 20-mL vial, which was her-
metically sealed. The sample underwent gentle agitation over the entire
length of the experiment. Experiments were performed in triplicate for sta-
tistical purposes. Because the PFCs used are dense and water-immiscible
liquids, the presence of PFCs should not have affected the concentration of
lipid vesicles in the sample. The control was made of the same vesicles in the
absence of PFCs.
Laurdan generalized polarization
Laurdan is an environmentally sensitive ﬂuorescent probe. The generalized
polarization (GP) of Laurdan ﬂuorescence is deﬁned as GP ¼ (I435  I500)/
(I4351 I500), where I435 and I500 are the ﬂuorescence intensities of Laurdan at
435 and 500 nm, respectively. The GP reﬂects membrane packing in the
polar-nonpolar interfacial regions (21), where the chromophore of Laurdan
resides (22,23). Higher GP values indicate tighter membrane packing. The
concentration of Laurdan stock solution in dimethylsulfoxide (DMSO) was
determined photometrically at 364 nm, using the extinction coefﬁcient e
equal to 20,000 cm1M1 (in methanol).
Laurdan in DMSOwas added to the lipid vesicles ([POPC]¼ 300 mM) in
a probe/lipid molar ratio of 1:200. The mixture was incubated overnight
under argon and protected from light. The amount of DMSO added to the
sample was always,1% (v/v); this amount of DMSOwas previously shown
not to perturb membrane structure to any signiﬁcant extent (24). Then PFC
was added, and the vial was sealed. At each time point, 200 mL were taken
from the sample vial through a valve, such that the pressure generated by the
PFC vapor in the sample vial remained constant throughout the entire ex-
periment. The aliquot that was removed was added to a ﬂuorescence cuvette
containing 1.6 mL of Tris buffer. The emission spectrum of Laurdan was
recorded from 400–520 nm, with excitation wavelength set at 340 nm on an
ISS K2 ﬂuorometer (ISS, Champaign, IL).
Particle size and size distribution as determined
by dynamic light scattering
The hydrodynamic diameters of vesicles were measured at 25C by photon
correlation spectroscopy, using a Malvern Zetasizer 1000HAS spectrometer
(Malvern Instruments, Wores, UK). The light source was a 10-mW He-Ne
laser (633 nm), and the scattered light was measured at a right angle, using an
avalanche photodiode detector. Because very dilute solutions were used, the
values for the refractive index and viscosity were set equal to the values of
water for the calculations of hydrodynamic diameters. Speciﬁcally, the re-
fractive indexwas 1.33 for all samples examined, and the viscosity was 0.891
cP at 25C (in accordancewith the Handbook of Chemistry and Physics, 68th
ed.). The data were analyzed using the Contin algorithm (provided by
Malvern Instruments), which calculates the Z-average size and polydisper-
sity. The Z-average size is the average hydrodynamic diameter of the vesi-
FIGURE 1 Molecular structures of PFCs used in this study. (A) Perﬂuoro-2-
methylpentane (PP1). (B) Perﬂuoromethylcyclohexane (PP2). (C) Perﬂuoro-
1,3,5-trimethylcyclohexane (PP4). (D) Perﬂuoromethyldecalin, mixture of
several isomers (PP9).
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cles, whereas polydispersity is a measure of the width of the vesicle size
distribution.
Energy transfer between NBD-PE and
rhodamine-DHPE: a lipid-mixing assay
Concentrations of stock solutions of NBD-PE and rhodamine-DHPE dis-
solved in chloroform were determined photometrically, using the extinction
coefﬁcients eNBD-PE ¼ 21,000 cm1M1 (in methanol at 463 nm), and
erhodamine-DHPE ¼ 75,000 cm1M1 (in methanol at 560 nm). The LUVs
(;200 nm in diameter), composed of POPC/cholesterol/NBD-PE or POPC/
cholesterol/rhodamine-DHPE (molar ratio, 69:30:1), were prepared as de-
scribed earlier.
An equimolar mixture of POPC/cholesterol/NBD-PE and POPC/choles-
terol/rhodamine-DHPE LUVs (150 mM total lipid in each population) was
incubated with PFC, as described earlier. At each time point, 200 mL were
removed from the sample vial through a valve. The aliquot was added to a
cuvette containing 1.6 mL of Tris buffer for ﬂuorescence readings. The
emission spectrum was recorded from 500–620 nm on an SLM 8000C ﬂuo-
rometer (SLM Instruments, Urbana, IL), with an excitation wavelength set
at 450 nm. The emission spectrum should exhibit two peaks: one is centered
at 530 nm because of the emission of NBD-PE, and the other appears at
;585 nm, corresponding to the emission from rhodamine-DHPE.
The resonance energy transfer between NBD-PE (donor) and rhodamine-
DHPE (acceptor) can occur if these two probes are in close proximity be-
cause of lipid mixing between these two vesicle populations. Lipid-mixing
can occur through vesicle coalescence or vesicle fusion. As a result of lipid
mixing, the peak intensity at 585 nm, relative to that at 530, was enhanced.
The extent of energy transfer is reﬂected by the parameter E ¼ (INBD 
IRhod)/(INBD1 IRhod), where INBD and IRhod are the ﬂuorescence intensities at
530 nm and 585 nm, respectively. The limiting value of E ranges between
1 and1, corresponding to 0 and 100% energy transfer, respectively. Amore
negative E value indicates more energy transfer and more lipid-mixing.
Electron and phase contrast microscopy
The effects of PFCs on themorphology and aggregation state of lipid vesicles
were examined by negative staining-transmission electron microscopy (EM)
and phase-contrast microscopy. The sample for negative-staining EM was
prepared as described (25). Brieﬂy, 10-mL aliquots of 0.10% (w/v) of a poly-
L-lysine solution (in water) were placed on carbon-coated 400-mesh Cu
grids. Excess volume was removed by adsorption with Whatman No. 2 ﬁlter
paper at the edge of the grid, and the remaining poly-L-lysine solution was
allowed to dry for 10 min on the grid before the addition of sample; 10 ml
aliquots of sample were added to the poly-L-lysine-coated Cu grids for 5 s,
and washed with a controlled stream of 5–6 drops of 2% uranyl acetate stain
(pH 4.8). The grid was then air-dried for 5 min before loading into the mi-
croscope. Negatively stained areas of samples were examined by bright-ﬁeld
transmission EM at an accelerating voltage of 80 kV in a Philips CM12 cryo-
version scanning-transmission electron microscope (FEI Co., Inc., Hillsboro,
OR). For phase-contrast microscopy, an inverted optical microscope (Model
IRBE, LeicaMicrosystems, Bannockburn, IL), equipped with phase-contrast
lenses and a halogen lamp house, was used.
RESULTS
Fig. 2 shows the effects of PFCs on the average diameter and
polydispersity of vesicle particles composed of cholesterol
(30 mol %) and POPC (70mol %) at room temperature. In the
presence of PP1 and PP2 (high vapor pressure PFCs; Fig. 1),
both the particle size and size distribution (polydispersity)
increased abruptly with time during phases I (time ¼ 0–2 h)
and II (time ¼ 2–8 h) (Fig. 2). In phase III (time ¼ 8–120 h),
the size and size distribution increased with time much less
dramatically, and approached a plateau near the end of the
experiment (Fig. 2). Low vapor pressure PFCs (PP4 and PP9;
Fig. 1) produced a much smaller and slower increase in
particle size and size distribution over time. The timescale for
PFC-induced particle size change was consistent with the
report that PFC uptake into cell membranes is relatively slow
and takes several hours to reach equilibrium (26). During this
experimental time period (0–120 h), the control (the same
vesicles in the absence of PFCs) showed very little change in
size (average diameter, 186.5 6 15.8 nm) and size distribu-
tion (polydispersity, 0.076 6 0.031). To rule out the emul-
siﬁcation of PFCs in the aqueous solution, we mixed PP1,
PP2, PP4, and PP9 with Tris buffer, and the mixtures were
gently agitated for the same number of hours. For this control,
there was no detection of particles by photon correlation
FIGURE 2 Temporal evolution of particle size (A) and polydispersity (B)
in the presence of (d) PP1, (s) PP2, (n) PP4, and (h) PP9, in liposomes
composed of POPC (70 mol %)and cholesterol (30 mol %). Control (vesicles
in absence of PFCs): vesicle size ¼ 186.5 6 15.8 nm, and polydispersity ¼
0.0766 0.031, over time period of 120 h. Three different stages described in
text are indicated by I, II, and III.
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spectroscopy, suggesting that the dramatic increase in parti-
cle size and size distribution seen in Fig. 2 was attributable to
direct interaction between PFCs and lipid membranes.
Fig. 3 shows that high vapor pressure PFCs (e.g., PP1 and
PP2) can also induce remarkable changes in particle size for
POPC LUVs in the absence of cholesterol. However, the rate
of particle-size increase for POPC vesicles was signiﬁcantly
slower than that for POPC/cholesterol (30 mol %) (Fig. 3,
inset). Bilayer membranes of pure POPC are not supposed to
possess lipid microdomains. In contrast, sterol superlattice
domains exist in POPC/cholesterol (30 mol %) mixtures
(27,28).
An additional experiment was designed to test whether the
extent of sterol superlattice affects the rate of PFC-induced
vesicle aggregation/fusion (Fig. 4). In this experiment,
POPC/cholesterol vesicles with three different sterol mole
fractions were used. We chose 22.2 mol %, because it is one
of the critical sterol mole fractions (Cr) for maximal sterol
superlattices (28–30), and used 21.0 and 23.4 mol %, because
they are two noncritical mole fractions in the neighborhood
of the critical mole fraction 22.2 mol %. As shown in Fig. 4,
the particle size increased considerably over time upon ex-
posure to PP1 for vesicles at noncritical sterol mole fractions
(e.g., 21.0 and 23.4 mol %), but increased little for vesicles at
the critical sterol mole fraction 22.2 mol %. This result (Fig.
4) indicates that the rate of particle-size increase engendered
by PP1 depends on the extent of sterol superlattice. This kind
of remarkable biphasic change in membrane properties at Cr
was described previously (20,27,28).
To understand the origin of the particle-size increase
produced by PFCs, an energy-transfer assay was performed
to assess the degree of lipid-mixing between vesicles in the
presence of PFCs. Lipid-mixing may result from vesicle fu-
sion, vesicle coalescence, and lipid spontaneous transfer
between vesicles. In this experiment, the emission spectrum
of an equimolar mixture of vesicles composed of POPC/
cholesterol/NBD-PE (molar ratio, 69:30:1) and POPC/cho-
lesterol/rhodamine-DHPE (molar ratio, 69:30:1) was mea-
sured as a function of PP1 exposure time (Fig. 5). The peak
intensity at 585 nm (because of rhodamine-DHPE), relative
to that at 530 nm (because of NBD-PE), increased over time
(Fig. 5). From the emission spectra, the extent of lipid-mixing
between NBD-PE and rhodamine-DHPE from their origi-
nally separated vesicles can be determined in terms of the
energy transfer parameter E ¼ (INBD  IRhod)/(INBD1 IRhod)
(as deﬁned in Materials and Methods). Comparing the en-
ergy-transfer data in the presence and absence of PP1 (1PP1
and PP1, respectively, in Fig. 6 A), it can be seen that the
spontaneous transfer of NBD-PE and rhodamine-DHPE be-
tween vesicles contributes no more than 30% of the total
lipid-mixing. The E values obtained from samples in the
presence of PP1 minus the E values obtained from samples in
the absence of PP1 because of spontaneous lipid transfer
gives DE (labeled as (1PP1)-(PP1), Fig. 6 A, lower panel).
TheDE value reﬂects the PP1-induced energy transfer caused
by lipid-mixing attributable to vesicle coalescence or fusion.
A more negative value ofDEmeans a higher extent of vesicle
coalescence or fusion. It is clear from the DE data (Fig. 6 A,
lower panel) that PP1 induces a dramatic increase in vesicle
coalescence or fusion in the ﬁrst 5 h of PP1 exposure. This
process continues, but at a slower rate, after t ¼ 5 h.
The lipid composition in the equimolar mixture of POPC/
cholesterol/NBD-PE (molar ratio, 69:30:1) and POPC/cho-
lesterol/rhodamine-DHPE (molar ratio, 69:30:1) is not the
same as that in the POPC/cholesterol (molar ratio, 7:3) used
in the previous experiment (Fig. 2). Therefore, the effect of
FIGURE 3 Time dependence of particle size of vesicles composed of
POPC/cholesterol (30 mol %) (solid circles and squares) and POPC alone
(open circles and squares) upon exposure to PP1 (circles) and PP2
(squares). For each sample set, vesicle size at time zero was normalized
to one. (Inset) Enlarged plot for data points obtained during ﬁrst 8 h.
FIGURE 4 Time variation of particle size of vesicles composed of POPC/
cholesterol upon exposure to PP1. Experiments were performed using three
different cholesterol mole fractions: 21.0 (solid squares), 22.2 (open
circles), and 23.4 (solid triangles) mol %; 22.2 mol % is a critical mole
fraction (Cr) for centered rectangular superlattices, whereas 21.0 and 23.4
mol % are non-Cr values. [POPC] ¼ 300 mM.
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PP1 on particle size in this equimolar mixture was exam-
ined. As shown in Fig. 6 B, PP1 causes a signiﬁcant increase
in particle size of this equimolar mixture over a time period
of 47 h (1PP1, Fig. 6 B). In comparison, the same sample in
the absence of PP1 (PP1, Fig. 6 B) exhibits much less
change in particle size because of spontaneous vesicle ag-
gregation in the same time period (PP1, Fig. 6 B). The net
size change (Dsize) attributable to PP1 is expressed as
(1PP1)-(PP1) (Fig. 6 B, lower panel). It is clear from the
Dsize data that PP1 induces a signiﬁcant particle-size in-
crease, and that the rate of size increase undergoes an abrupt
change at t ¼ 5 h. The PP1-induced net increase in particle
size (Dsize, Fig. 6 B) correlates well (correlation coefﬁcient,
0.9) with the extent of lipid-mixing (DE, Fig. 6 A). This
implies that the PP1-induced and PP2-induced sharp in-
crease in particle size seen in Fig. 2 is likely attributable to
lipid-mixing resulting from either vesicle coalescence or
vesicle fusion.
The suggestion of vesicle fusion and coalescence is
strongly supported by phase-contrast microscopy (Fig. 7) and
negative-staining EM (Fig. 8) data. Fig. 7 shows that after
exposure to PP1 and PP2 (high vapor pressure PFCs) for
72 h, cholesterol/POPC vesicles (;200 nm originally) be-
come giant spherical vesicles at sizes of 20–40 mm. The
spherical shape and large size (Fig. 7) can be explained most
likely by multiple vesicle fusion, i.e., fusion involving more
than two vesicles (31). Our result shows for the ﬁrst time, to
our knowledge, that high vapor pressure PFCs have strong
fusogenic activity with lipid vesicles. In contrast, low vapor
pressure PFCs such as PP4 and PP9 produce fewer and much
smaller giant vesicles, some of which are aggregated with
small vesicles (Fig. 7).
If the giant vesicles observed in Fig. 7 are attributable to
vesicle fusion involving multiple vesicles, we might be able
to capture EM pictures for prefusion stages, such as vesicle
coalescence. Fig. 8 shows that this is probably the case. The
EM picture in Fig. 8 shows vesicle coalescence after cho-
lesterol/POPC vesicles were exposed to PP2 for 72 h. It is
notable, as seen in Fig. 8, that internal vesicular structures
exist inside each of the two opposing vesicles.
As such, the abrupt increase in particle size in region I
shown in Fig. 2 can be attributed to vesicle aggregation,
followed by immediate vesicle coalescence or vesicle fusion.
Vesicle aggregation is a prerequisite of vesicle coalescence
and fusion. Vesicle aggregation is known to involve lipid
headgroup dehydration and headgroup conformational
changes, especially at the sites of vesicle contacts (32). It is
then reasonable to predict that membrane packing in the
headgroup regions is altered during the time course of PFC
exposure. This prediction was tested by Laurdan’s GP, which
is known to be sensitive to membrane packing in membrane-
water interfacial regions (23,33–35).
The effects of PFCs on Laurdan’s GP in the cholesterol/
POPC (molar ratio, 3:7) vesicles are presented in Fig. 9. In all
cases examined, there was an initial increase in GP in region I
(;1 or 2 h after exposure to PFCs), followed by a steady
decrease in GP over time (Fig. 9, regions II and III). An in-
crease in GP implies an increase in membrane-packing
tightness or less water in the membrane polar headgroup
regions (36). A decrease in GP signals a disordering effect on
membrane structure (36). It appears from Figs. 2 and 6–9 that
membrane packing in the polar headgroup regions is closely
related to PFC-induced vesicle aggregation/fusion. The GP
value of the control (same Laurdan-containing vesicles in the
FIGURE 5 Fluorescence emission spectra of an equimolar mixture of two vesicle populations (NBD-PE/POPC/cholesterol and rhodamine-DHPE/POPC/
cholesterol) in the absence (PP1) and presence (1PP1) of PP1 after 0.25, 2, 6, 20, and 40 h of incubation at room temperature under gentle agitation.
Excitation was set at 450 nm. Peaks at 525 and 585 nm, measured at room temperature under gentle stirring, correspond to NBD-PE and rhodamine-DHPE
emission, respectively. Fluorescence intensity at 525 nm is normalized to unity. The PP1-induced energy transfer from NBD-PE to rhodamine-DHPE is clearly
observable at .6 h.
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absence of PFCs) remained virtually unchanged throughout
the entire experiment, indicating that the GP changes ob-
served were attributable to PFCs, and not to the instability of
Laurdan-probe molecules over time.
DISCUSSION
The particle-size change induced by PP1, PP2, PP4, and PP9
is dramatic. It would be interesting to link these data with the
respective membrane-water partition coefﬁcients of the
PFCs, which, however, are unknown at present. The partition
coefﬁcient of PFCs into membranes is determined by the
combination of vapor pressure and lipid solubility. Mem-
brane lipid solubility of the chosen PFCs is also unknown.
Therefore, our interpretation of the data focused on vapor
pressure. The PFCs PP1, PP2, PP4, and PP9 cover a broad
range of vapor pressures, and the vapor pressure has bio-
logical relevance, as mentioned earlier.
When cholesterol (30 mol %)/POPC vesicles are exposed
to high vapor pressure PFCs such as PP1 and PP2, there is a
dramatic increase in particle size from 186 nm to 350–500 nm
in the ﬁrst 2 h (Fig. 2). The vesicle-size increase is correlated
with lipid-mixing (Fig. 6), which suggests that high vapor
pressure PFCs induce vesicle coalescence or vesicle fusion
from an early time of PFC exposure. The size increase cannot
be attributed purely to vesicle-swelling, which may lead to
;5–73% increase in vesicle size (37,38), and not the 200–
300% shown in Fig. 2. The rate of particle-size increase
observed in POPC (Fig. 3) and cholesterol (30 mol %)/POPC
(Fig. 2) vesicles is much faster than that observed for vesicles
FIGURE 6 Temporal evolution of energy transfer (A) and particle size (B)
of equimolar mixtures of POPC/cholesterol/NBD-PE and POPC/cholesterol/
rhodamine-DHPE at room temperature in the presence (d) and absence (s)
of PP1.
FIGURE 7 Phase-contrast microscopy shows that exposure of cholesterol
(30 mol %)/POPC (70 mol %) unilamellar vesicles (;200 nm at time zero)
to PP1 and PP2, both of which are high vapor pressure PFCs, for 72 h results
in giant spherical vesicles of sizes;20–40 mm, probably because of vesicle
fusion. Giant vesicles are far fewer and smaller when exposed to PP4 and
PP9; both are low vapor pressure PFCs. Bar, 10 mm.
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composed of cholesterol/POPC/dye (NBD-PE or rhodamine-
DHPE) (Fig. 6). This difference may be attributed to the
repulsive interactions between vesicles carrying these ﬂuo-
rescent probes. At neutral pH, both NBD-PE and rhoda-
mine-DHPE have a negative net charge that hinders vesicle
aggregation, and subsequent vesicle coalescence and fusion.
Nevertheless, the general trend that high vapor pressure PFCs
induce vesicle coalescence or vesicle fusion,, and thus a
dramatic increase in particle size, holds true for all the lipid
vesicles investigated.
Fig. 2 also shows that high vapor pressure PFCs (i.e., PP1
and PP2) behave very differently from low vapor pressure
PFCs (i.e., PP4 and PP9) in terms of changing vesicle sizes. It
is likely that low vapor pressure PFCs do not induce vesicle
aggregation as much as do high vapor pressure PFCs. Vesicle
aggregation is a prerequisite of vesicle coalescence and fu-
sion. Many studies showed that vesicle aggregation is often
followed by vesicle fusion (31,39). In this study, our EM and
phase-contrast microscopy data (Figs. 7 and 8), as well as
energy-transfer studies (Figs. 5 and 6 A), suggest extensive
lipid-mixing and massive vesicle fusion after incubation with
PP1 and PP2. In comparison, low vapor pressure PFCs (PP4
and PP9) produced much less vesicle fusion (Fig. 7). Ag-
gregation is known to be promoted by lipid polar headgroup
dehydration (40). Elevated hydrostatic pressure is able to
reduce lipid headgroup water content, according to Czeslik
FIGURE 8 Negative-staining electron microscopy obtained from choles-
terol (30 mol %)/POPC (70 mol %) after incubation with PP2 for 72 h.
Image shows vesicle aggregation and coalescence. Bar, 200 nm.
FIGURE 9 Temporal evolution of Laurdan’s generalized polarization (GP) of POPC/cholesterol vesicles in the presence of (A) PP1, (B) PP2, (C) PP4, and
(D) PP9. Open circles indicate vesicles incubated with PFC; solid circles indicate vesicles in absence of PFCs. (Insets) Details of ﬁrst 8 h of GP proﬁle. Three
different stages described in text are indicated as I, II, and III.
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et al. (41). Although the hydrostatic pressure range used in
the study of Czeslik et al. (41) was 3–4 orders of magnitude
higher than the vapor pressure dealt with in this study, it is
still possible that the high vapor pressures possessed by PP1
and PP2 promote headgroup dehydration, and as a result
produce more vesicle aggregation than the low vapor pres-
sures of PP4 and PP9. The vapor pressure generates an os-
motic pressure because of differences in solute concentration
inside and outside the membrane. Thus, the force applied to
the membrane because of osmotic pressure is directional. In
contrast, the hydrostatic pressure experienced by a membrane
is nondirectional.
Another factor contributing to massive vesicle fusion is the
high PFC concentration gradient across the membrane. Be-
cause PFC liquids are immiscible with water and have a
higher density than water, they remain at the bottom of the
vial, surrounded by the aqueous suspensions of vesicles. In
the experimental setting used here, PFC molecules can mi-
grate from liquid droplets through the aqueous phase into the
gas phase. In equilibrium, a constant amount of PFC mole-
cules in the gas phase will create the vapor pressure and a
constant rate of exchange of PFC molecules across the PFC
liquid-water, water-gaseous phase, and water-membrane in-
terfaces. The hydrophobic nature of PFC molecules allows
them to partition into lipid membranes, and possibly migrate
into the vesicle lumen. When the sample is exposed to higher
vapor pressure PFC liquids (e.g., PP1 and PP2), more indi-
vidual PFC molecules can enter the aqueous phase from PFC
liquid droplets or from the gaseous phase. This will generate
a high PFC concentration gradient across the vesicular
membrane, which may cause microdomain sinking (42) or
vesicle-swelling (43,44).
Microdomain sinking was directly visualized by ﬂuores-
cence microscopy on membranes that were under a chemical
or mechanical stress such as a large concentration gradient
across the membrane (42). Microdomains are known to exist
in our cholesterol-containing samples (Figs. 2, and 4–8).
When subject to a high PFC concentration gradient, the in-
terfacial regions between the highly ordered lipid micro-
domains (e.g., sterol superlattices (20) or lipid rafts (45)) and
the rather disordered bulk domains are frustrated, leading to
microdomain sinking (or vesicular endocytosis) (42). Mi-
crodomains may also occur in cholesterol-free membranes in
the presence of PFC liquids (Fig. 3). Perﬂuorocarbons are
lipophilic, but they also tend to form liquid droplets. There-
fore, after individual PFC molecules insert into lipid mem-
branes, they may aggregate to form lateral domains in the
membrane. These domains can, in principle, undergo domain
sinking under a high PFC concentration gradient. This ex-
plains why high vapor pressure PFCs can also induce con-
siderable changes in particle size in cholesterol-free POPC
vesicles, although the rate of the size change is signiﬁcantly
slower (Fig. 3).
The data in Fig. 4 further suggest that the rate of PFC-
induced particle-size increase varies with lipid-membrane
domain size, i.e., the extent of sterol superlattice in the
membrane. When the extent of sterol superlattice (super-
lattice domain) is small, which occurs at noncritical mole
fractions such as 21.0 and 23.4 mol % sterol in POPC, the
initial rate of particle-size change is relatively fast (Fig. 4).
When the extent of sterol superlattice (superlattice domain) is
large (;71–89% of the total surface area at critical sterol
mole fractions, Cr) (46,47), the initial rate of particle-size
change becomes relatively slow (22.2 mol % cholesterol, Fig.
4). These data (Fig. 4), taken together with the data shown in
Fig. 3, suggest that when the domain does not exist (POPC
only, Fig. 3) or is too big (22.2 mol % sterol, Fig. 4), high
vapor pressure PFCs induce less vesicle fusion. When the
domain exists but the domain size is moderate (in the cases of
21.0 and 23.4 mol % sterol in POPC, Fig. 4), high vapor
pressure PFCs induce more dramatic vesicle fusion (Figs.
2 and 4), probably because of increased domain sinking.
Microdomain sinking (42) is likely to create transient
membrane defects, through which membrane fusion starts
(42). Cell studies showed that PFCs can enter the cytoplasm
and form vacuole-like particles (48,49). Those particles may
be associated with internalized membranes with entrapped
PFC liquids. The EM picture in Fig. 8 displays internal ve-
sicular structures in opposing vesicles; this seems to be in
good agreement with our domain-sinking hypothesis.
The presence of small amounts of NBD-PE and rhoda-
mine-DHPE, both of which possess bulky polar headgroups,
may attenuate the formation of cholesterol-related liquid-
ordered domains such as sterol superlattices (20,28,29). It is
then possible that PP1-induced domain-sinking is less in the
mixture of POPC/cholesterol/NBD-PE and POPC/choles-
terol/rhodamine-DHPE than in cholesterol (30 mol %)/POPC
bilayers. This, in addition to the surface charge mentioned
earlier, also explains why the PP1-induced particle-size
change in this particular mixture (Fig. 6 B) is less dramatic
than in the mixture of cholesterol (30 mol %) and POPC (Fig.
2 A).
Vesicle-swelling is also known to induce vesicle fusion
(38,43,44). However, the data in Fig. 3 seem to argue against
this possibility. Vesicle-swelling is supposed to be more
difﬁcult in cholesterol-containing PC vesicles than in pure
PC bilayers, because cholesterol is known to stabilize (con-
dense) ﬂuid lipid bilayers. In this sense, the data in Fig. 3
(inset) do not support the vesicle-swelling hypothesis, but do
agree with the domain-sinking model. Microdomains are
supposed to be more abundant in cholesterol-containing PC
vesicles than in pure PC bilayers. Our data show that the
initial rate of the PP1-induced or PP2-induced particle-size
increase with time is less for POPC than for POPC-choles-
terol (molar ratio, 7:3) mixtures (Fig. 3, inset).
Another factor contributing to vesicle fusion could be the
possible high level of PFC partitioning into lipid vesicles in
the cases of PP1 and PP2. The insertion of PFC may disrupt
membrane packing, which creates local membrane defects
and leads to vesicle fusion (42).
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Molecular events such as vesicle aggregation, swelling,
domain-sinking, and vesicle fusion can be used to explain the
GP data (Fig. 9). There is an initial increase in GP in region I
for all PFCs examined (Fig. 8). This initial increase in GP is
likely attributable to vesicle aggregation, which is usually
accompanied by headgroup dehydration. When the water
level near the lipid polar headgroup regions is reduced, the
GP value becomes high (21). The subsequent steady decrease
in GP with time (Fig. 9, regions II and III) may be attributable
to a gradual disruption of membrane structure as a result of
domain-sinking or vesicle-swelling or PFC insertion, as well
as vesicle fusion. When exposed to high vapor pressure PFCs
such as PP1 and PP2, the initial increase in GP in cholesterol/
POPC mixtures is less than that observed from low vapor
pressure studies. A possible explanation is that, when ex-
posed to PP1 and PP2, a large number of small vesicles ag-
gregate. Moreover, when vesicle aggregation occurs,
domain-sinking or vesicle-swelling will also begin. The
former increases GP, whereas the latter decreases GP. Be-
cause of these opposite effects, the initial GP increase at-
tributable to PP1 and PP2 is less, compared with PP4 and
PP9.
When exposed to PP4 and PP9 (low vapor pressures),
vesicle aggregation may also occur, but the aggregates may
involve a smaller number of original vesicles. Thus, particle
size does not increase much in region I (Fig. 2). However, this
limited vesicle aggregation still leads to vesicle fusion, al-
though to a much lower extent, as evidenced by the data in
Figs. 2 and 7. In this case, aggregation itself gives rise to an
increase in GP, but the opposite effect on GP attributable to
domain-sinking, vesicle-swelling, and vesicle fusion is rela-
tively little. As a result, there is a larger initial increase in GP
(Fig. 9, region I) for PP4 and PP9.
The origin of the antiinﬂammatory effect of PFCs is un-
clear. Perﬂuorocarbons do not affect direct binding between
the ligand (e.g., concanavalin A) and the receptor (e.g.,
mannosylated glycoprotein) (50). Woods et al. reported that
the diffusion of perﬂubron (a PFC) from the alveolar space
into the pulmonary vascular endothelial layer may modulate
neutrophil adhesion, and thereby reduce the rate of inﬁltra-
tion of activated neutrophils into the injured lung (26). Chang
et al. suggested that FC-77 (a PFC) inhibits inﬂammatory
responses in lipopolysaccharide-stimulated macrophages by
attenuating the nuclear factor NF-kB-dependent induction
of the cyclooxygenase-2/prostaglandin E2 pathway and
the proinﬂammatory/antiinﬂammatory cytokine ratio (51).
Haeberle et al. reported that treatment with perﬂubron abro-
gated NF-kB activation in the lungs of respiratory syncytial
virus-infected mice (13). Nuclear factor NF-kB is a protein
controlling the gene expression of proinﬂammatory media-
tors (52). Because it is known that the activation of NF-kB
can be affected by membrane proteins and lipids (53, 54) and
by surface active agents such as detergents and anesthetics
(55), it is logical to suggest that PFCs cause marked changes
in membrane fusion and membrane packing, as revealed in
this study, which in turn cause changes in the activation of
NF-kB, thus inducing antiinﬂammatory responses. A few
other studies also proposed that PFCs perturb the cell mem-
brane, subsequently altering intracellular signal-transduction
pathways (15,48,50,56–58). Perﬂuorocarbons inﬂuence the
release and expression of proinﬂammatory mediators in a
nonspeciﬁc manner, in accordance with the idea that the ef-
fects of PFCs involve cell-membrane modiﬁcation (15,50).
As shown in Fig. 7, exposure of vesicles to high vapor
pressure PFCs can lead to giant vesicles of 20–40 mm. This
represents a new way, we believe, to generate giant vesicles
for microscopy studies. Whether the PFC-induced giant
vesicles are unilamellar or not is yet to be determined.
In conclusion, our results show for the ﬁrst time, to our
knowledge, that high vapor pressure PFCs have strong fu-
sogenic activity with lipid vesicles, particularly those with
moderate lipid microdomains, and can produce marked
changes in membrane packing in a time-dependent manner.
These results may help elucidate the molecular mechanisms
of PFC-membrane interactions in cells. This level of under-
standing may improve the use and development of biomed-
ical applications of PFCs (see Introduction), and will prove
helpful in choosing appropriate PFC physiochemical prop-
erties to rationalize the design of PFC treatments.
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